Physician profile
Sohail Khan
NPI 1235330382
$4,244.77
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,301 · 2020: $596 · 2021: $901 · 2022: $430 · 2023: $15.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,672.98 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $1,020.27 | 2019 | |
| Medtronic, INC. | $194.88 | 2021-2022 | |
| Boston Scientific Corporation | $182.55 | 2019-2020 | |
| Abiomed | $136.09 | 2019 | |
| Amgen INC. | $123.55 | 2019-2020 | |
| Angiodynamics, INC. | $122.31 | 2021 | |
| Inari Medical, INC. | $101.13 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $93.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $92.99 | 2019-2020 | |
| Penumbra, INC. | $84.01 | 2019 | |
| Pfizer INC. | $72.72 | 2019 | |
| Philips North America LLC | $64.30 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $45.96 | 2019 | |
| W. L. Gore & Associates, INC. | $45.44 | 2022-2023 | Viabahn Endoprosthesis With Propaten Bioactive Surface |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $39.36 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.38 | 2019 | |
| Lantheus Medical Imaging, INC. | $24.86 | 2019 | |
| Portola Pharmaceuticals, LLC | $22.54 | 2019 | |
| Cardinal Health 200 LLC | $20.13 | 2019 | |
| Chiesi USA, INC. | $16.82 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.48 | 2019 | |
| Amarin Pharma, INC. | $12.84 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sohail Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.